CD47 and cancer: Treating CD44hi/CD24low cancer stem cells with the CD47 blocking antibody B6H12 suppressed asymmetric division (Figure 4b), stem cell transcription factors including Klf4 (Figure 4c) cell growth, and induced executioner caspase-7 activity.